The advent of novel therapeutics that specifically target signaling pathways activated by
genetic alterations has revolutionized the way patients with lung cancer are treated …

Based on recent bench and clinical research, the treatment of lung cancer has been refined,
with treatments allocated according to histology and specific molecular features. For …

The identification of molecular subtypes of non-small-cell lung cancer has transformed the
clinical management of this disease. This is best exemplified by the clinical success of …

Lung cancer is a heterogeneous, complex, and challenging disease to treat. With the arrival
of genotyping and genomic profiling, our simple binary division of lung cancer into non-small …

We are currently in an era of rapidly expanding knowledge about the genetic landscape and
architectural blueprints of various cancers. These discoveries have led to a new taxonomy of …

Lung cancer remains the leading cause of cancer-related mortality worldwide. The
application of next-generation genomic technologies has offered a more comprehensive …

In lung cancer, genomics-driven comprehensive molecular profiling has identified novel
chemically and immunologically addressable vulnerabilities, resulting in an increasing …

The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational
development of targeted drugs for patient populations stratified by genetic characteristics …

Substantial advances have been made in understanding critical molecular and cellular
mechanisms driving tumor initiation, maintenance, and progression in non–small-cell lung …

We characterized genome alterations in 1255 clinically annotated lung tumors of all
histological subgroups to identify genetically defined and clinically relevant subtypes. More …